keyword
MENU ▼
Read by QxMD icon Read
search

Pain management metastatic prostate cancer

keyword
https://www.readbyqxmd.com/read/28314320/the-clinical-efficacy-of-enzalutamide-in-metastatic-prostate-cancer-prospective-single-center-study
#1
Giuseppe Cicero, Rossella DE Luca, Patrizia Dorangricchia, Francesco Dieli
BACKGROUND/AIM: To evaluate the effectiveness of enzalutamide in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer, progressing after chemotherapy with docetaxel plus prednisone. PATIENTS AND METHODS: A total of 60 patients were enrolled. Reduction in serum prostate-specific antigen (PSA) was assessed as the primary endpoint, while reduction in pain, safety, progression-free survival and overall survival represented secondary endpoints...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28256271/impact-of-locally-advanced-or-metastatic-prostate-cancer-on-the-quality-of-life
#2
I López-Calderero, L López-Fando, E Ríos-González, P Maisonobe, E Hernández-Yuste, M Sarmiento-Jordán
OBJECTIVE: The aim of this study was to assess the health-related quality of life of patients with prostate cancer in advanced phases to obtain additional information on the patients' health. The growing interest in understanding the patient's perspective and the scarcity of prospective studies of this population motivated this research study. MATERIAL AND METHODS: We present an observational study performed on 131 urology consultations, with a sample of 601 patients with locally advanced or metastatic prostate cancer, assessed during 2 visits: baseline and at 12 months...
February 27, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28156585/pilot-study-of-incorporating-a-supportive-care-program-into-a-small-community-oncology-practice
#3
Kelly Schultz, Jennifer Thompson, Michael Thomas Byrne, Andrew J Buresh, Brendan F Curley
149 Background: Incorporation of supportive care has become standard of care in patients with advanced or metastatic cancer undergoing palliative chemotherapy. Implementation of a supportive care program is often difficult in a small community practice due to a multitude of factors. METHODS: We piloted a supportive care program with the partnership of Sage Hospice & Palliative Care in which patients with advanced or metastatic cancer undergoing chemotherapy would be evaluated by a certified nurse practitioner (CNP)...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27988895/radiopharmaceuticals-for-metastatic-bone-pain-palliation-available-options-in-the-clinical-domain-and-their-comparisons
#4
REVIEW
Tapas Das, Sharmila Banerjee
Bone pain arising due to skeletal metastases is one of the common complications experienced by the majority of patients suffering from prostate, breast and lung cancer at the advanced stage of the disease. These patients are subjected to palliative care in order to improve the quality of their remaining life. With the gradually increasing number of cancer cases, palliation of metastatic bone pain is gaining importance. Bone-seeking radiopharmaceuticals play a pivotal role in the management of cancer pain, particularly in patients with multiple metastases, as these agents are proven to be effective in controlling the bone pain with minimum side effects...
January 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/27960186/cabazitaxel-in-metastatic-castration-resistant-prostate-cancer-patients-progressing-after-docetaxel-a-prospective-single-center-study
#5
Giuseppe Cicero, Rossella De Luca, Patrizia Dorangricchia, Antonio Galvano, Giuseppe Lo Re, Vincenzo Serretta, Nino Dispensa, Francesco Dieli
PURPOSE: The present study aims to evaluate the efficacy of cabazitaxel in combination with prednisone treatment in Italian patients affected by hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel plus prednisone. METHODS: Thirty patients with mCRPC were enrolled between June 2013 and January 2016 (the last follow-up was in January 2016). Cabazitaxel was used according to the summary of product characteristics and administered at a dose of 25 mg/m2 every 3 weeks plus oral prednisone at a dose of 5-mg tablets twice a day continuously...
2017: Oncology
https://www.readbyqxmd.com/read/27878318/-corticosteroids-in-the-management-of-advanced-prostate-cancer
#6
H Kübler
Corticosteroids have been widely used for decades in cancer therapy, predominantly due to their anti-inflammatory activity. In the treatment of metastatic castration-resistant prostate cancer (mCRPC), corticosteroids play an important role both in the management of tumor-related symptoms, especially bone metastasis-related pain, and as concomitant treatment to counteract side effects associated with approved active prostatic anticancer agents such as docetaxel, cabazitaxel, and abiraterone acetate. In association with abiraterone acetate, low-dose corticosteroids (prednisone or prednisolone) reduce the mineralocorticoid side effects of abiraterone...
February 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27843209/radioisotopes-in-management-of-metastatic-prostate-cancer
#7
REVIEW
Amar Raval, Tu D Dan, Noelle L Williams, Andrew Pridjian, Robert B Den
INTRODUCTION: Metastatic prostate cancer continues to be a leading cause of morbidity and mortality in men with prostate cancer. Over the last decade, the treatment landscape for patients with castrate-resistant disease has drastically changed, with several novel agents demonstrating an improvement in overall survival in large, multi-institutional randomized trials. Traditional treatment with radioisotopes has largely been in the palliative setting. However, the first in class radiopharmaceutical radium-223 has emerged as the only bone-directed treatment option demonstrating an improvement in overall survival...
October 2016: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/27694165/bone-targeted-imaging-and-radionuclide-therapy-in-prostate-cancer
#8
Andrei H Iagaru, Erik Mittra, Patrick M Colletti, Hossein Jadvar
Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds-such as (18)F-NaF for the diagnosis of bony disease and (223)RaCl2 for the therapy of bone metastases-were recently shown to be superior to standard (99m)Tc-phosphonates for diagnosis and (153)Sm-ethylenediaminetetramethylene phosphonate or (89)SrCl2 for therapy. The advantages of (18)F-NaF include improved lesion detection and, when used in combination with CT, improved diagnostic confidence and specificity...
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27692731/-prevalence-and-management-of-pain-in-patients-with-metastatic-cancer-in-franche-comt%C3%A3
#9
MULTICENTER STUDY
Fanny Dénommé, Marie Kroemer, Philippe Montcuquet, Gilles Nallet, Antoine Thiery-Vuillemin, Fernando Bazan, Guillaume Mouillet, Cristian Villanueva, Martin Demarchi, Ulrich Stein, Hamadi Almotlak, Loïc Chaigneau, Elsa Curtit, Nathalie Meneveau, Tristan Maurina, Erion Dobi, Thierry Nguyen Tan Hon, Laurent Cals, Laura Mansi, Clotilde Verlut, Héloïse Pana-Katatali, Mathieu Caubet, Marie-Justine Paillard, Samuel Limat, Xavier Pivot, Virginie Nerich
INTRODUCTION: Pain management is a major public health problem, especially in oncology. In order to assess professional practice, the IRFC-FC conducted a survey amongst patients with metastatic osteophilic solid tumor in Franche-Comté. The aims were to assess the pain prevalence, and its characteristics, its management and its impact on patients' quality of life in patients in pain. METHODS: An observational, prospective and multicenter survey was conducted using a self-report questionnaire...
October 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27465596/a-rare-case-of-extremely-high-counts-of-circulating-tumor-cells-detected-in-a-patient-with-an-oral-squamous-cell-carcinoma
#10
Xianglei Wu, Romina Mastronicola, Qian Tu, Gilbert Charles Faure, Marcelo De Carvalho Bittencourt, Gilles Dolivet
BACKGROUND: Despite aggressive regimens, the clinical outcome of head and neck squamous cell carcinoma remains poor. The detection of circulating tumor cells could potentially improve the management of patients with disseminated cancer, including diagnosis, treatment strategies, and surveillance. Currently, CellSearch(®) is the most widely used and the only Food and Drug Administration-cleared system for circulating tumor cells detection in patients with metastatic breast, colorectal, or prostate cancer...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27457309/esmo-european-consortium-study-on-the-availability-out-of-pocket-costs-and-accessibility-of-antineoplastic-medicines-in-europe
#11
N Cherny, R Sullivan, J Torode, M Saar, A Eniu
BACKGROUND: The management of cancer is predicated on the availability and affordability of anticancer therapies, which may be either curative or noncurative. AIM: The primary aims of the study were to evaluate (i) the formulary availability of licensed antineoplastic medicines across Europe; (ii) patient out-of-pocket costs for the medications and (iii) the actual availability of the medication for a patient with a valid prescription. MATERIALS AND METHODS: The survey tool was based on the previous ESMO studies that addressed the availability and accessibility of opioids for the management of cancer pain...
August 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27390687/degarelix-for-the-treatment-of-advanced-prostate-cancer-compared-with-gnrh-agonists-a-systematic-review-and-meta-analysis
#12
Seyed Alireza Hosseini, Fatemeh Rajabi, Ali Akbari Sari, Mohsen Ayati, Saeed Heidari, Fawzieh Ghamary
BACKGROUND: Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. We performed a systematic review to compare safety, efficacy and effectiveness of degarelix, a new gonadotropin-releasing hormone (GnRH) antagonist (blocker), versus gonadotropin-releasing hormone (GnRH) agonists. METHODS: MEDLINE, Web of Science and the Cochrane library were searched to identify all of the published Randomized Controlled Trials (RCTs) that used degarelix versus gonadotropin-releasing hormone agonists with or without anti-androgen therapy for the treatment of prostate cancer...
2016: Medical Journal of the Islamic Republic of Iran
https://www.readbyqxmd.com/read/27385897/metastasis-in-urothelial-carcinoma-mimicking-prostate-cancer-metastasis-in-ga-68-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-in-a-case-of-synchronous-malignancy
#13
Manoj Gupta, Partha Sarathi Choudhury, Gurudutt Gupta, Jatin Gandhi
Prostate cancer is the second most common cancer in man. It commonly presents with urinary symptoms, bone pain, or diagnosed with elevated prostate-specific antigen.(PSA) levels. Correct staging and early diagnosis of recurrence by a precise imaging tool are the keys for optimum management. Molecular imaging of prostate cancer with Ga-68 prostate-specific membrane antigen.(PSMA), positron emission tomography-computed tomography.(PET-CT) has recently received significant attention and frequently used with a signature to prostate cancer-specific remark...
July 2016: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/27380753/clinical-applications-of-high-intensity-focused-ultrasound
#14
REVIEW
W H She, T T Cheung, C R Jenkins, M G Irwin
Ultrasound has been developed for therapeutic use in addition to its diagnostic ability. The use of focused ultrasound energy can offer a non-invasive method for tissue ablation, and can therefore be used to treat various solid tumours. High-intensity focused ultrasound is being increasingly used in the treatment of both primary and metastatic tumours as these can be precisely located for ablation. It has been shown to be particularly useful in the treatment of uterine fibroids, and various solid tumours including those of the pancreas and liver...
August 2016: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/27244207/spontaneous-healing-of-mandibular-noncontinuous-defect-caused-by-medication-related-osteonecrosis-of-the-jaw
#15
Mürüde Yazan, Fethi Atil, Ismail Doruk Kocyigit, Umut Tekin, Hakan Hifzi Tuz, Melda Misirlioglu
BACKGROUND: Bisphosphonates are used throughout supportive cancer therapies for the treatment of osteoporosis and metastatic bone diseases, but they invariably induce medication-related osteonecrosis of the jaw (MRONJ). This medicational modality may induce consequential losses that can lead to spontaneous or surgical therapy related bone fractures or defects. MRONJ stages and treatment alternatives are described in the current procedures. Accordingly, treatments for stages 0 and 1 are conservative whereas the treatment for stage 3 is surgical resection of the necrotic bone...
June 2016: Journal of Craniofacial Surgery
https://www.readbyqxmd.com/read/27141135/ivory-vertebra-imaging-findings-in-different-diagnoses
#16
Richard Andreas Braun, Carlos Felipe do Rego Barros Milito, Suzan Menasce Goldman, Eloy de Ávila Fernandes
Low back pain is often managed at all levels of healthcare. In general, diagnostic investigation begins with radiography of the lumbar spine. In addition to the most common findings, radiologists can identify increased density of a vertebral body, referred to as ivory vertebra. The objective of this study was to describe the main diseases that can present with this radiologic sign, such as Hodgkin lymphoma, Paget's disease, metastatic prostate cancer, breast cancer, and osteomyelitis. It is extremely important that radiologists be aware of this finding in order to inform the requesting physician of the possible etiologies, given that it can be the initial radiologic presentation for these diseases...
March 2016: Radiologia Brasileira
https://www.readbyqxmd.com/read/26905032/practical-guidance-on-the-role-of-corticosteroids-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer
#17
Maria De Santis, Fred Saad
Corticosteroids have been used in combination with chemotherapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for more than three decades, particularly to treat pain, inflammation, and edema. More recently, they have been used in combination with hormonal agents. The importance of corticosteroids in mCRPC is due to their ability to manage adverse effects, reduce symptoms, and improve patients' quality of life. The appropriate selection of available options in mCRPC should be based on careful consideration of a patient's profile and comorbidities...
February 18, 2016: Urology
https://www.readbyqxmd.com/read/26656603/heterogeneity-of-tumor-cells-in-the-bone-microenvironment-mechanisms-and-therapeutic-targets-for-bone-metastasis-of-prostate-or-breast-cancer
#18
REVIEW
Mitsuru Futakuchi, Katsumi Fukamachi, Masumi Suzui
Bone is the most common target organ of metastasis of prostate and breast cancers. This produces considerable morbidity due to skeletal-related events, SREs, including bone pain, hypercalcemia, pathologic fracture, and compression of the spinal cord. The mechanism of bone metastasis is complex and involves cooperative reciprocal interaction among tumor cells, osteoblasts, osteoclasts, and the mineralized bone matrix. The interaction between the metastatic tumor and bone stromal cells has been commonly referred to as the "vicious cycle"...
April 1, 2016: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/26445599/abiraterone-in-the-management-of-castration-resistant-prostate-cancer-prior-to-chemotherapy
#19
REVIEW
Benjamin A Gartrell, Fred Saad
The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone acetate and enzalutamide), chemotherapeutics (docetaxel and cabazitaxel), an autologous vaccine (sipuleucel-T) and a radiopharmaceutical (radium-223). Abiraterone acetate, a prodrug of abiraterone, inhibits the CYP17A enzyme, a critical enzyme in androgen biosynthesis...
August 2015: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/26335695/gabapentin-an-analgesic-used-against-cancer-associated-neuropathic-pain-effects-on-prostate-cancer-progression-in-an-in-vivo-rat-model
#20
Ilknur Bugan, Zeynep Karagoz, Seyhan Altun, Mustafa B A Djamgoz
A major problem associated with clinical management of cancer is controlling the accompanying pain, and various analgesics are in common use for this purpose. Recent evidence suggests that some of the targets of analgesics, such as ion channels and receptors, may also be involved in the cancer process, thereby raising the possibility that such use of some analgesics may impact upon cancer itself. The main aim of this study was to determine whether gabapentin, a common adjuvant analgesic in current use against cancer-associated neuropathic pain, would affect tumour development and progression in vivo...
March 2016: Basic & Clinical Pharmacology & Toxicology
keyword
keyword
76764
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"